Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Chronic myelogenous leukemia (CML)

Protein phosphatase 2 (PPP2CA; PP2A)

Studies in patient samples and mice suggest Gilenya fingolimod and nonimmunosuppressive derivatives could help eradicate leukemic stem cells in CML, which are associated with disease relapse. In leukemic hematopoietic stem cells (HSCs) isolated from patients with CML, PP2A activity was lower than that in healthy HSCs. In the CML stem cells, Gilenya or any of three nonimmunosuppressive derivatives activated PP2A, impaired self-renewal and induced apoptosis. In mouse xenograft models of CML, Gilenya decreased leukemic stem cell numbers compared with no treatment. Next steps include designing additional PP2A activators.
Novartis AG markets the sphingosine 1-phosphate receptor agonist Gilenya to treat relapsing forms of multiple sclerosis (MS).
Oncotide Pharmaceuticals Inc. has SET nuclear oncogene (SET) inhibitors in preclinical development to treat various cancers. SET inhibition is designed to activate PP2A.

SciBX 6(38); doi:10.1038/scibx.2013.1060
Published online Oct. 3, 2013

Multiple patent applications filed covering nonimmunosuppressive derivatives and their use in various cancers; available for licensing and partnering from The Ohio State University Technology Commercialization and Knowledge Transfer Office

Neviani, P. et al. J. Clin. Invest.; published online Sept. 3, 2013;
doi:10.1172/JCI68951
Contact: Danilo Perrotti, University of Maryland, College Park, Md.
e-mail:
dperrotti@som.umaryland.edu